Sofosbuvir: First Global Approval

doi:10.1007/s40265-014-0179-7

2014-01-18

PRE

Keating, Gillian M.

Vaidya, Asha *

DOI：10.1007/s40265-014-0179-7

原文链接

原文求助

摘要

En 中文

Sofosbuvir (Solvadi (TM)), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral regimen. In addition, the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sofosbuvir for the treatment of chronic hepatitis C. This article summarizes the milestones in the development of sofosbuvir leading to this first approval for chronic hepatitis C.

Keyword:

TREATMENT-NAIVE PATIENTS

HEPATITIS-C INFECTION

DRUG-DRUG INTERACTION

HIGH SVR RATES

HCV GENOTYPE 1

PLUS RIBAVIRIN

IN-VITRO

GS-7977

HEALTHY

RESISTANCE

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

adis international

学者数:

102

论文数: 386

被引数: 0

引用论文

Sofosbuvir-based interferon-free therapy for patients with HCV infection

JOURNAL OF HEPATOLOGY

IF33

2013-12-01

OAAI

Asselah, Tarik

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

LANCET

IF88.5

2014-02-01

471

PREAI

Lawitz, Eric; Poordad, Fred F.; Pang, Phillip S.; Hyland, Robert H.; Ding, Xiao; Mo, Hongmei; Symonds, William T.; McHutchison, John G.; Membreno, Fernando E.

Current prospects for interferon-free treatment of hepatitis C in 2012

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2012-12-19

PREAI

Stedman, Catherine A. M.

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

LANCET

IF88.5

2013-06-01

240

PREAI

Kowdley, Kris V.; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell N.; DeMicco, Michael; Bernstein, David E.; Afdhal, Nezam; Vierling, John M.; Gordon, Stuart C.; Anderson, Jane K.; Hyland, Robert H.; Dvory-Sobol, Hadas; An, Di; Hindes, Robert G.; Albanis, Efsevia; Symonds, William T.; Berrey, M. Michelle; Nelson, David R.; Jacobson, Ira M.

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2013-05-16

1.6K

OAAI

Lawitz, Eric; Mangia, Alessandra; Wyles, David; Rodriguez-Torres, Maribel; Hassanein, Tarek; Gordon, Stuart C.; Schultz, Michael; Davis, Mitchell N.; Kayali, Zeid; Reddy, K. Rajender; Jacobson, Ira M.; Kowdley, Kris V.; Nyberg, Lisa; Subramanian, G. Mani; Hyland, Robert H.; Arterburn, Sarah; Jiang, Deyuan; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Sheikh, Aasim M.; Younossi, Zobair; Gane, Edward J.

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2013-05-16

922

OAAI

Jacobson, Ira M.; Gordon, Stuart C.; Kowdley, Kris V.; Yoshida, Eric M.; Rodriguez-Torres, Maribel; Sulkowski, Mark S.; Shiffman, Mitchell L.; Lawitz, Eric; Everson, Gregory; Bennett, Michael; Schiff, Eugene; Al-Assi, M. Tarek; Subramanian, G. Mani; An, Di; Lin, Ming; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Patel, Keyur; Feld, Jordan; Pianko, Stephen; Nelson, David R.

Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence 丙型肝炎病毒感染的全球流行病学: 年龄特异性抗体对HCV血清阳性率的新估计

HEPATOLOGY

IF15.8

2013-04-01

1.9K

OAAI

Hanafiah, Khayriyyah Mohd; Groeger, Justina; Flaxman, Abraham D.; Wiersma, Steven T.

ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938

JOURNAL OF HEPATOLOGY

IF33

2013-04-01

OAAI

Guedj, J.; Pang, P. S.; Lawitz, E.; Rodriguez-Torres, M.; Symonds, B.; Perelson, A. S.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

LANCET INFECTIOUS DISEASES

IF31

2013-05-01

260

PREAI

Lawitz, Eric; Lalezari, Jay P.; Hassanein, Tarek; Kowdley, Kris V.; Poordad, Fred F.; Sheikh, Aasim M.; Afdhal, Nezam H.; Bernstein, David E.; DeJesus, Edwin; Freilich, Bradley; Nelson, David R.; Dieterich, Douglas T.; Jacobson, Ira M.; Jensen, Donald; Abrams, Gary A.; Darling, Jama M.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Sulkowski, Mark S.; Bzowej, Natalie H.; Hyland, Robert H.; Ho, Hongmei; Lin, Ming; Mader, Michael; Hindes, Robert; Albanis, Efsevia; Symonds, William T.; Berrey, Michelle M.; Muir, Andrew

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2013-01-03

635

OAAI

Gane, Edward J.; Stedman, Catherine A.; Hyland, Robert H.; Ding, Xiao; Svarovskaia, Evguenia; Symonds, William T.; Hindes, Robert G.; Berrey, M. Michelle

查看更多内容